NeoGenomics

NeoGenomics

Health Care Providers & Services
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

$2.5B

Market Cap • 9/28/2026

1998

(28 years)

Founded

1996

(30 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

3,2

P/S

3,2

P/EBITDA

—

P/OCF

112,4

P/FCF

—

P/E

—

BVPS

6,1

EPS

—

Market Cap

Market Cap

2,5B

EV

2,8B

EV/Revenue

3,6

EV/EBITDA

-1044,4

EV/EBIT

-40,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

1%

Total Yield

1%

Payout

0%

Retained Earnings

-448,7M

Profitability

Gross Margin

43,9%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

5%

Capex/Revenue

3,8%

Capex/D&A

44,7%

Capex/OCF

133,4%

SBC/OCF

164,2%

% PPE

12,3%

% Goodwill

38,8%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

9,4%

CAGR Op. Income 5Y

20,2%

CAGR OCF 5Y

24,6%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

3,6

Quick Ratio

3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium